Pressure BioSciences Announces First Commercial Production of Revolutionary UltraShear Nanoemulsion Product Shipped, Booked, and Paid
December 13th, 2022
App, News, Top News
$75,000 Pilot Lot Payment Received for Phase I of Safer Medical of Montana Agreement; Phases II/III Commercial Scale-Up Scheduled for Early 2023 – Expected to Yield 1st Half 2023 Revenues Over $1 Million
SOUTH EASTON, MA / ACCESSWIRE / December 13, 2022 / Pressure BioSciences, Inc. (OTCQB:PBIO) (“PBI” or “Company”), a leader in the development and sale of broadly enabling, pressure-based instruments, consumables, and specialty process development and production services to the worldwide nutraceuticals, cosmetics, biotherapeutics, and food/beverage industries, among others, today confirmed the shipment of the Company’s first ever commercial production lot of a revolutionary nanoemulsion product created and enabled by the Company’s innovative Ultra Shear Technology™ (UST™ or UltraShear™) nanoemulsification platform. The shipped product is a breakthrough CBD oral spray designed by PBI for fast effect and high potency for Safer Medical of Montana (“SMM”), with whom PBI signed a multi-year development and manufacturing agreement (“Agreement”), announced on May 4, 2022. SMM pre-paid the entire $75,000 purchase price of the Phase I production lot.
The Agreement covers three phases of development and commercialization of a custom-formulated oral spray of hemp-derived nanoemulsified CBD designed for extremely rapid absorption and effectiveness, and for efficient high potency delivery of CBD active material in each dose. All ingredients used in the manufacture of this UltraShear prepared nanoemulsion product are sourced from naturally-occurring, plant-based origins. Phases II and III of the PBI-SMM Agreement are focused on scaling up UltraShear nanoemulsion production by a factor of 10x in each stage, with total PBI revenues captured under this Agreement expected to top $1M in Q1/Q2 of 2023.
Captain George Ackerson, the CEO and Founder of Safer Medical of Montana, stated: “I am so excited by our opportunity to partner with Pressure BioSciences in allowing the launch of their first UltraShear-enabled nanoemulsion product to be focused upon creation of our revolutionary “Black Ops Nano CBD” oral spray, which is specifically targeted to serving vast unmet needs within the U.S. veterans community. Their UltraShear technology platform allows an oil-soluble active molecule like CBD to be prepared into a nanoemulsion of vanishingly tiny oil droplets in water that ensures rapid absorption and unparalleled bioavailability of the CBD into the water-based biochemistry of human bodies. Development work to date has demonstrated these capabilities far beyond any CBD products currently on the market – with performance better than we could have dreamed.”
Captain Ackerson continued: “As a Vietnam veteran myself, I wanted to make certain that our CBD product had the best chance of helping the men and women who have served our Country, many of whom still struggle daily with significant health and wellness issues. To ensure optimal effectiveness with fast validation in a positive first use experience, we requested the development of a very high concentration of CBD (40mg per milliliter), which is beyond the concentration capabilities of currently marketed true nano formulations. Each bottle contains 2000mg of CBD. One spray will deliver about 6.5mg of the nanoemulsified CBD, designed for fast absorption through the cheek or under the tongue. Individual users will be able to adjust their dosage easily and rapidly as needed.”
Mr. John B. Hollister, Director of Sales and Marketing at PBI, observed: “This launches a new chapter for Pressure BioSciences, as UltraShear commercialization enters into a phase of scale up and rapid growth. PBI has long established itself as an expert in the development and application of extreme high-pressure technology to enable remarkable and important new scientific and production capabilities, but UltraShear now opens an extraordinarily broad range of important and large new commercial application markets, from pharmaceuticals to nutraceuticals, cosmetics, food and beverages, agrochemicals, and many more.”
Mr. Hollister continued: “Black Ops Nano CBD is the first UltraShear product, but vastly more products, far beyond this initial cannabinoid opportunity, will quickly follow. We have previously announced exciting progress in our cosmeceutical partnership with Dr. Denese SkinScience, and in our formulation developments for astaxanthin (the most potent antioxidant in the market) and other nutraceuticals. Our investors should expect to hear much more about additional UltraShear contracts and products in the days and weeks ahead. The dam is bursting.”
Mr. Richard T. Schumacher, President and CEO of PBI, concluded: We recently announced the first three cosmeceutical products targeted for development and commercialization with Dr. Adrienne Denese through the initial quarters of 2023 PBIO/Dr. Denese FORCE Webinar 101322. Combined with the CBD product formulations already announced with orders from Captain Ackerman and other partners, we expect these UltraShear products to yield at least $4 million of incremental new toll manufacturing revenues for PBI through Q1/Q2 of 2023. We are also close to executing a number of additional UltraShear contracts that we anticipate will drive Q3/Q4 2023 tolling revenues well beyond the expected Q1/Q2 record revenues created by the UltraShear platform. This is a wonderful time to consider becoming or being a stakeholder in Pressure BioSciences.”
About Pressure BioSciences, Inc.
Pressure BioSciences, Inc. (OTCQB: PBIO) is a leader in the development and sale of innovative, broadly enabling, pressure-based solutions for the worldwide life sciences and other industries. Our products are based on the unique properties of both constant (i.e., static) and alternating (i.e., pressure cycling technology, or PCT) hydrostatic pressure. PCT is a patented enabling technology platform that uses alternating cycles of hydrostatic pressure between ambient and ultra-high levels to control bio-molecular interactions safely and reproducibly (e.g., cell lysis, biomolecule extraction). Our primary focus is in the development of PCT-based products for biomarker and target discovery, drug design and development, biotherapeutics characterization and quality control, soil & plant biology, forensics, and counter-bioterror applications. Additionally, major new market opportunities have emerged in the use of our pressure-based technologies in the following areas: (1) the use of our recently acquired, patented technology from BaroFold, Inc. (the “BaroFold” technology) to allow entry into the bio-pharma contract services sector, and (2) the use of our recently-patented, scalable, high-efficiency, pressure-based Ultra Shear Technology (“UST”) platform to (i) create stable nanoemulsions of otherwise immiscible fluids (e.g., oils and water) and to (ii) prepare higher quality, homogenized, extended shelf-life or room temperature stable low-acid liquid foods that cannot be effectively preserved using existing non-thermal technologies.
Forward Looking Statements
This press release contains forward-looking statements. These statements relate to future events or our future financial performance and involve known and unknown risks, uncertainties and other factors that may cause our or our industry’s actual results, levels of activity, performance, or achievements to be materially different from any future results, levels of activity, performance or achievements expressed, implied, or inferred by these forward-looking statements. In some cases, you can identify forward-looking statements by terminology such as “may,” “will,” “should,” “could,” “would,” “expects,” “plans,” “intends,” “anticipates,” “believes,” estimates,” “predicts,” “projects,” “potential” or “continue” or the negative of such terms and other comparable terminology. These statements are only predictions based on our current expectations and projections about future events. You should not place undue reliance on these statements. In evaluating these statements, you should specifically consider various factors. Actual events or results may differ materially. These and other factors may cause our actual results to differ materially from any forward-looking statement. These risks, uncertainties, and other factors include, but are not limited to, the risks and uncertainties discussed under the heading “Risk Factors” in the Company’s Annual Report on Form 10-K for the year ended December 31, 2021, and other reports filed by the Company from time to time with the SEC. The Company undertakes no obligation to update any of the information included in this release, except as otherwise required by law.
For more information about PBI and this press release, please click on the following website link:
Please visit us on Facebook, LinkedIn, and Twitter.
Richard T. Schumacher, President & CEO (508) 230-1828 (T)
John B. Hollister, Director of Sales and Marketing (805) 908-5719 (T)
Jeffrey N. Peterson, Chairman (650) 703-8557(T)
SOURCE: Pressure BioSciences Inc.
This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.
Follow Us on Social Media
About CFN Media Group
CFN Enterprises Inc. (OTCQB: CNFN) owns and operates CFN Media Group, the premier agency and financial media network reaching executives, entrepreneurs and consumers worldwide. Through its proprietary content creation, video library, and distribution via www.CannabisFN.com, CFN has built an extensive database of cannabis interest, assisting many of the world’s largest cannabis firms and CBD brands to build awareness and thrive. For more information, please visit www.cfnenterprisesinc.com.
Disclaimer: Matters discussed on this website contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time-to-time have a position in the securities mentioned herein and will increase or decrease such positions without notice. The Information contains forward-looking statements, i.e. statements or discussions that constitute predictions, expectations, beliefs, plans, estimates, or projections as indicated by such words as "expects", "will", "anticipates", and "estimates"; therefore, you should proceed with extreme caution in relying upon such statements and conduct a full investigation of the Information and the Profiled Issuer as well as any such forward-looking statements. Any forward looking statements we make in the Information are limited to the time period in which they are made, and we do not undertake to update forward looking statements that may change at any time; The Information is presented only as a brief "snapshot" of the Profiled Issuer and should only be used, at most, and if at all, as a starting point for you to conduct a thorough investigation of the Profiled Issuer and its securities and to consult your financial, legal or other adviser(s) and avail yourself of the filings and information that may be accessed at www.sec.gov, www.pinksheets.com, www.otcmarkets.com or other electronic sources, including: (a) reviewing SEC periodic reports (Forms 10-Q and 10-K), reports of material events (Form 8-K), insider reports (Forms 3, 4, 5 and Schedule 13D); (b) reviewing Information and Disclosure Statements and unaudited financial reports filed with the Pink Sheets or www.otcmarkets.com; (c) obtaining and reviewing publicly available information contained in commonlyknown search engines such as Google; and (d) consulting investment guides at www.sec.gov and www.finra.com. You should always be cognizant that the Profiled Issuers may not be current in their reporting obligations with the SEC and OTCMarkets and/or have negative signs at www.otcmarkets.com (See section below titled "Risks Related to the Profiled Issuers, which provides additional information pertaining thereto). For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity-based compensation in the companies it writes about, or a combination of the two. For full disclosure, please visit: https://www.cannabisfn.com/legal-disclaimer/. A short time after we acquire the securities of the foregoing company, we may publish the (favorable) information about the issuer referenced above advising others, including you, to purchase; and while doing so, we may sell the securities we acquired. In addition, a third-party shareholder compensating us may sell his or her shares of the issuer while we are publishing favorable information about the issuer. Except for the historical information presented herein, matters discussed in this article contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time to time have a position in the securities mentioned herein and will increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity- based compensation in the companies it writes about, or a combination of the two. For full disclosure please visit: https://www.cannabisfn.com/legal-disclaimer/.